Literature DB >> 3095240

Immunogenic properties of Klebsiella pneumoniae type 2 capsular polysaccharide.

A Robert, H Jouin, J M Fournier.   

Abstract

The immunoprotective activity of Klebsiella pneumoniae K2 cell surface preparations and purified capsular polysaccharide was tested in mice. The 50% protective dose (PD50), expressed as capsular polysaccharide content, was 2 ng for cell surface preparations and 50 ng for purified capsular polysaccharide. Both preparations lost their immunoprotective activity after alkali treatment. Immune sera were raised in rabbits immunized with cell surface preparations. The precipitating and hemagglutinating capacity of these antisera was tested against either purified capsular polysaccharide or alkali-treated capsular polysaccharide. No difference was observed between the reactivity of the antisera against each antigen. The protective activity of these sera was tested on mice in passive transfer experiments, before and after absorption with either purified capsular polysaccharide or alkali-treated capsular polysaccharide. The sera lost their protective activity after absorption with purified capsular polysaccharide and after absorption with alkali-treated capsular polysaccharide. These experiments show that the difference in immunoprotective activity of cell surface preparations, purified capsular polysaccharide, and alkali-treated capsular polysaccharide is not due to a difference in their antigenic determinants. Cell surface preparations and purified capsular polysaccharide were fractionated by gel filtration on Sepharose 4B and by ultracentrifugation on cesium chloride density gradients. Three forms of capsular polysaccharide have been characterized. (i) A form of capsular polysaccharide with a very high protective activity (PD50 = 2 ng) that copurified with protein and lipopolysaccharide and was characterized by a low coefficient of distribution (Kd = 0.20) and a low density (1.5 to 1.6 g/cm3). (ii) A form of capsular polysaccharide with an intermediate protective activity (PD50 = 50 ng), contamined by less than 3% protein and 1% lipopolysaccharide, with a Kd of 0.35, and a density of 1.7 to 1.8 g/cm3. (iii) A nonimmunoprotective capsular polysaccharide obtained after alkali treatment of either cell surface preparations or purified capsular polysaccharide. The Kd of these fractions varied from 0.20 to 0.90 and their density from 1.7 to 1.8 g/cm3.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095240      PMCID: PMC260170          DOI: 10.1128/iai.54.2.365-370.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  New method for quantitative determination of uronic acids.

Authors:  N Blumenkrantz; G Asboe-Hansen
Journal:  Anal Biochem       Date:  1973-08       Impact factor: 3.365

2.  Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens.

Authors:  J M Cooper; D Rowley
Journal:  Aust J Exp Biol Med Sci       Date:  1982-12

3.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

4.  Purification and vaccine potential of Klebsiella capsular polysaccharides.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

5.  Immunochemical characterization of the outer membrane complex of Bacteroides fragilis subspecies fragilis.

Authors:  D L Kasper; M W Seiler
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

6.  Conformation of crystalline type III pneumococcal polysaccharide.

Authors:  R H Marchessault; K Imada; T Bluhm; P R Sundararajan
Journal:  Carbohydr Res       Date:  1980-08-15       Impact factor: 2.104

7.  A new polyvalent Pseudomonas vaccine.

Authors:  J M Miler; J F Spilsbury; R J Jones; E A Roe; E J Lowbury
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

8.  Immunochemical characterization of surface antigens of Bacteroides melaninogenicus.

Authors:  B J Mansheim; A B Onderdonk; D L Kasper
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

9.  Direct evidence for the involvement of capsular polysaccharide in the immunoprotective activity of Klebsiella pneumoniae ribosomal preparations.

Authors:  M M Riottot; J M Fournier; H Jouin
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

10.  Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.